<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">OXYBUTYNIN CHLORIDE</span><br/>(ox-i-byoo'ti-nin)<br/><span class="topboxtradename">Ditropan, </span><span class="topboxtradename">Ditropan XL, </span><span class="topboxtradename">Oxytrol<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">anticholinergic (parasympatholytic)</span>; <span class="classification">antimuscarinic</span>; <span class="classification">antispasmodic</span><br/><b>Prototype: </b>Atropine<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5 mg tablets; 5 mg, 10 mg sustained-release tablets; 5 mg/5 mL syrup; 3.9 mg/d transdermal patch</p>
<h1><a name="action">Actions</a></h1>
<p>Synthetic tertiary amine that exerts direct antispasmodic action and inhibits muscarinic effects of acetylcholine on smooth
         muscle.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Prominent antispasmodic activity.</p>
<h1><a name="uses">Uses</a></h1>
<p>To relieve symptoms associated with voiding in patients with uninhibited neurogenic bladder and reflex neurogenic bladder.
         Also has been used to relieve pain of bladder spasm following transurethral surgical procedures.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity of oxybutynin; narrow angle glaucoma, myasthenia gravis, partial or complete GI obstruction, gastric retention,
         paralytic ileus, intestinal atony (especially older adult or debilitated patients), megacolon, severe colitis, GU obstruction,
         urinary retention, unstable cardiovascular status.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Older adults; autonomic neuropathy, hiatus hernia with reflex esophagitis; hepatic or renal dysfunction; urinary infection;
         hyperthyroidism; CHF, coronary artery disease, hypertension; prostatic hypertrophy; pregnancy (category B), children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Neurogenic Bladder</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 5 mg b.i.d. or t.i.d. (max: 20 mg/d) or 5 mg sustained-release q.d., may increase up to 30 mg/d <span class="rdroute">Topical</span> Apply 1 patch twice weekly<br/><span class="rdage">Geriatric:</span> <span class="rdroute">PO</span> 2.55 mg b.i.d. (max: 15 mg/d) or 5 mg sustained-release q.d., may increase up to 30 mg/d <span class="rdroute">Topical</span> Apply 1 patch twice weekly<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> <i>15 y,</i> 0.2 mg/kg b.i.d.q.i.d.; &gt;<i>5 y,</i> 5 mg b.i.d. (max: 15 mg/d)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Ensure that sustained-release form is not chewed or crushed. It must be swallowed whole.</li>
</ul><span class="adminroutetype">Topical</span><br/><ul>
<li>Ensure that old patch is removed prior to application of new patch.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Severe allergic reactions including urticaria, skin rashes, suppression of lactation, decreased sweating, fever. <span class="typehead">CNS:</span> <span class="speceff-common">Drowsiness,</span> dizziness, weakness, insomnia, restlessness, psychotic behavior (overdosage). <span class="typehead">CV:</span> Palpitations, tachycardia, flushing. <span class="typehead">Special Senses:</span>  Mydriasis, <span class="speceff-common">blurred vision,</span> cycloplegia, increased ocular tension. <span class="typehead">GI:</span> <span class="speceff-common">Dry mouth,</span> nausea, vomiting, <span class="speceff-common">constipation,</span> bloated feeling. <span class="typehead">Skin:</span> <i>Pruritus at application site,</i> rash, application site vesicles, erythema. <span class="typehead">Urogenital:</span> Urinary hesitancy or retention, impotence. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Diffuses across intact skin. <span class="typehead">Onset:</span> 0.51 h. <span class="typehead">Peak:</span> 36 h. <span class="typehead">Duration:</span> 610 h. <b>PO:</b> 96 h Transdermal. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted primarily in urine. <span class="typehead">Half-Life:</span> 25 h 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Periodic interruptions of therapy are recommended to determine patient's need for continued treatment. Tolerance has occurred
            in some patients.
         </li>
<li>Keep physician informed of expected responses to drug therapy (e.g., effect on urinary frequency, urgency, urge incontinence,
            nocturia, completeness of bladder emptying).
         </li>
<li>Monitor patients with colostomy or ileostomy closely; abdominal distension and the onset of diarrhea in these patients may
            be early signs of intestinal obstruction or of toxic megacolon.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not drive or engage in potentially hazardous activities until response to drug is known.</li>
<li>Exercise caution in hot environments. By suppressing sweating, oxybutynin can cause fever and heat stroke.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>